Mannkind Stock Price, News & Analysis

MannKind Corporation (Nasdaq: MNKD) has announced the acquisition of scPharmaceuticals in a deal valued up to $360 million. The transaction includes an upfront payment of $5.35 per share plus a CVR worth up to $1.00 per share tied to regulatory and sales milestones.

The acquisition brings FUROSCIX, an FDA-approved treatment for fluid overload in chronic heart failure and chronic kidney disease patients, with a $10+ billion U.S. market opportunity. scPharmaceuticals reported strong H1 2025 performance with net sales of $27.8 million, up 96% year-over-year. The combined company projects an annualized revenue run rate of over $370 million based on Q2 2025 results.

The deal is expected to close in Q4 2025, with Blackstone providing $175 million in additional funding. A FUROSCIX ReadyFlow Autoinjector sNDA submission is planned for Q3 2025, potentially reducing treatment time from five hours to under 10 seconds.

MannKind Corporation (Nasdaq: MNKD) has secured a strategic financing agreement worth up to $500 million with Blackstone. The deal includes a $75 million initial term loan at closing, a $125 million delayed draw term loan available for 24 months, and an additional $300 million uncommitted DDTL.

The non-dilutive financing, maturing in August 2030, bears interest at SOFR plus 4.75%. The funds will support MannKind's growth initiatives, including the commercial team expansion for Afrezza's potential pediatric indication, pipeline advancement, and business development opportunities.

MannKind Corporation (Nasdaq: MNKD) reported strong Q2 2025 financial results with total revenues of $76.5 million, up 6% year-over-year. The company achieved net income of $0.7 million in Q2 2025, compared to a net loss of $2.0 million in Q2 2024.

Key highlights include the submission of an sBLA for Afrezza in pediatric patients, with a review decision expected in early Q4 2025. The company's pipeline is advancing with the ICoN-1 trial for inhaled clofazimine (MNKD-101) enrollment ahead of schedule, and plans to initiate a Phase 2 trial for nintedanib DPI (MNKD-201) in IPF by year-end 2025.

Revenue growth was driven by a 22% increase in royalties from Tyvaso DPI sales and a 13% increase in Afrezza revenue to $18.3 million. The company maintained a strong financial position with $201.2 million in cash and investments as of June 30, 2025.

MannKind Corporation (NASDAQ: MNKD) has scheduled its second quarter 2025 financial results announcement for August 6, 2025, before the market opens. The company will host a conference call and webcast at 9:00 a.m. Eastern Time to discuss the results and provide business updates.

The presentation will be accessible through MannKind's investor relations website, with a replay available for approximately 90 days after the event.

MannKind Corporation (MNKD) will present key data on their inhaled insulin product Afrezza at the American Diabetes Association's 85th Scientific Sessions in Chicago from June 20-23, 2025. The presentations will feature results from multiple studies, including the INHALE-1 clinical trial for pediatric patients aged 4-17 years, presented by Dr. Michael J. Haller. Additional presentations will cover patient-reported outcomes and results from a Phase III trial in India for adult Type 2 diabetes patients. The company plans to release complete pediatric study results in Q2 2025 and submit a Supplemental Biologics License Application for pediatric indication by mid-2025.

MannKind Corporation (MNKD) is partnering with NTT INDYCAR SERIES driver Conor Daly for a special event during the Chevrolet Detroit Grand Prix week. The event, scheduled for May 29, 2025, at Full-Throttle Adrenaline Park in Novi, MI, will feature Daly sharing his experience living with Type 1 diabetes and racing go-karts with local youth.

Daly, diagnosed with T1D at age 14, is the only known U.S. professional racing driver competing full-time with the condition. He will drive the No. 76 "Tired of Pricks?" Chevrolet for Juncos Hollinger Racing at the Detroit Grand Prix. His notable achievements include a career-best 6th place finish at the 2022 Indy 500, leading the most laps at the 2021 Indy 500, and becoming the first driver to compete in both NASCAR and IndyCar on consecutive Texas weekends in 2023.

MannKind Corporation (MNKD), a company specializing in inhaled therapeutic products for endocrine and orphan lung diseases, has announced its participation in two upcoming investor conferences. CEO Michael Castagna and CFO Chris Prentiss will present at:

- RBC Capital Markets 2025 Global Annual Healthcare Conference on Tuesday, May 20 at 8:00 a.m. ET

- Jefferies Global Healthcare Conference on Thursday, June 5 at 2:35 p.m. ET

Both conferences will be held in New York City. Live audio webcasts will be available on MannKind's investor relations website, with recordings accessible for approximately 90 days after the events.

MannKind Corporation (MNKD) reported strong Q1 2025 financial results with total revenues of $78.4M, up 18% year-over-year. The company achieved net income of $13.2M (up 24%) and non-GAAP net income of $21.6M (up 43%). Revenue growth was driven by increased Tyvaso DPI royalties and collaboration services. Afrezza showed strong performance with 20% NRx growth and 14% TRx growth. Key pipeline developments include plans to submit sBLA for Afrezza in pediatric patients mid-2025, progress in MNKD-101's Phase 3 trial for NTM lung disease with 55 patients randomized, and advancement of MNKD-201 program. The company maintained a strong financial position with $198M in cash and equivalents as of March 31, 2025.

MannKind Corporation (MNKD) has scheduled its Q1 2025 financial results announcement for May 8, 2025, before market open. The company will host a webcast at 9:00 a.m. Eastern Time featuring CEO Michael Castagna and CFO Chris Prentiss to discuss the quarterly results and provide a business update. The webcast will be available through MannKind's investor relations website, with a replay accessible for approximately 90 days following the call.